ENTRY       D11701                      Drug
NAME        Luspatercept (USAN/INN);
            Luspatercept (genetical recombination) (JAN);
            Luspatercept-aamt;
            Reblozyl (TN)
PRODUCT     REBLOZYL (Celgene Corporation)
FORMULA     C3350H5070N906O1044S38
EXACT_MASS  75910.0875
MOL_WEIGHT  75958.0146
SEQUENCE    ETRECIYYNA NWELERTNQS GLERCEGEQD KRLHCYASWR NSSGTIELVK KGCWDDDFNC
            YDRQECVATE ENPQVYFCCC EGNFCNERFT HLPEAGGPEV TYEPPPTGGG THTCPPCPAP
            ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR
            EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP
            PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV
            DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK
            (Disulfide bridge: 5-35, 25-53, 60-79, 66-78, 80-85, 114-114', 117-117', 149-209, 255-313, 5'-35', 25'-53', 60'-79', 66'-78', 80'-85', 149'-209', 255'-313')
  TYPE      Peptide
REMARK      ATC code: B03XA06
            Product: D11701<US>
EFFICACY    Anti-anemic, Erythroid maturation agent
  DISEASE   beta Thalassemia [DS:H00228]
COMMENT     Treatment of anemia associated with ineffective erythropoiesis
TARGET      ACVR2B [HSA:93] [KO:K13596]
  PATHWAY   hsa04060(93)  Cytokine-cytokine receptor interaction
            hsa04350(93)  TGF-beta signaling pathway
            hsa04550(93)  Signaling pathways regulating pluripotency of stem cells
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             B BLOOD AND BLOOD FORMING ORGANS
              B03 ANTIANEMIC PREPARATIONS
               B03X OTHER ANTIANEMIC PREPARATIONS
                B03XA Other antianemic preparations
                 B03XA06 Luspatercept
                  D11701  Luspatercept (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Blood Products and Modifiers
              Blood Products and Modifiers, Other
               Blood Products and Modifiers, Micellaneous
                Luspatercept
                 D11701  Luspatercept (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor serine/threonine kinases (RSTK)
               TGFBR2 family
                ACVR2B
                 D11701  Luspatercept (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11701
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11701
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11701
DBLINKS     CAS: 1373715-00-4
            PubChem: 405226567
///
